A pediatric ciliopathy ecosystem

with a therapeutic pipeline addressing genetic diseases of the kidney, retina, bone and cartilage

A pediatric ciliopathy ecosystem

with a therapeutic pipeline addressing genetic diseases of the kidney, retina, bone and cartilage

Our Ecosystem

Supported since its creation in 2019 by Institut Imagine and Inserm Transfert, MEDETIA has been working for four years to identify and accelerate emerging therapeutic drug innovations.

Imagine is a research and innovative healthcare institute of a new type, bringing together researchers, doctors and patients, with a common goal: to undersand, diagnose and cure genetic diseases.



In 2019, Medetia was supported by the Human Health Startup Factory consortium, and it was granted DeepTech labelling.

In 2021, Medetia has been selected for inclusion in the Challenges media’s “100 start-ups to invest in in 2021” in the Medtech and Biotech category; also it was one recipient of the i-Lab innovation competition.

In 2023, MEDETIA announces its partnership with Ipsen, an international biopharmaceutical group, within the framework of the innovative research program Hybridge™, based on the prospection of medicine candidates for rare diseases.


Ciliopathies are a large family of genetic diseases whose common feature is a dysfunction of the primary cilia – affecting kidney, retina and cartilage, but not only.

Medetia is – since 2019 – has been part of the RHU (« Recherche Hospitalo-Universitaire en santé » ) consortium C’IL-LICO, as industrial partner. The C’IL-LICO project proposes a new approach for the management of a group of rare and serious genetic diseases, ciliopathies that cause the deterioration of renal function and lead to end-stage renal failure. (Image modified swissbiopics.org)


At Medetia, we have consolidated a proprietary and customisable methodology to tackle complex drug discovery challenges, by combining cutting-edge technologies, proven pharmacological and medical solutions with an unique approach on Intellectual Property.

Featured news


Signature of a durable partnership with IPSEN signed

Press Release Inserm-Transfer >

Press Release IPSEN >

Imagine Institute Press Release >


Medetia consolidates its position at Imagine Institute with a master research agreement



Medetia signs master research agreement with Inserm Transfer


Article published in Pharmaceutiques.com about Medetia

Read the Article >


New positive in vivo data for MDT-110 sustaining application in LCA10

Read More >


Medetia published its initial POC in PNAS

Read the Publication >

About Us


Jean-Philippe Annereau
CEO & Co-Founder

Lead the strategic orientation and gouvernance. 20y experience in Pharma Industry.

Luis Briseño Roa
CTO & Co-Founder

Accelerator of partnerships, with strong pharma and biotech experience.

Get in Touch